{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43.2","upperLimit":"63.6","value":"53.5"},{"groupId":"OG001","lowerLimit":"42.4","upperLimit":"62.2","value":"52.4"},{"groupId":"OG002","lowerLimit":"37.4","upperLimit":"74.5","value":"56.7"},{"groupId":"OG003","lowerLimit":"47.2","upperLimit":"67.2","value":"57.4"},{"groupId":"OG004","lowerLimit":"54.6","upperLimit":"73.9","value":"64.7"},{"groupId":"OG005","lowerLimit":"28.5","upperLimit":"48.0","value":"37.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"105"},{"groupId":"OG002","value":"30"},{"groupId":"OG003","value":"101"},{"groupId":"OG004","value":"102"},{"groupId":"OG005","value":"103"}],"units":"Participants"}],"description":"DCR was defined per RECIST 1.1 as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) or Stable Disease (SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD: At least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm\\]). The appearance of one or more new lesions is also considered PD.\\]). For participants with GBM, response was assessed according to RANO criteria whereby overall response was based on both radiographic response (CR: disappearance of all target lesions, PR: sum of products of diameters \\[SPD\\] decreased by ≥ 50% from baseline value and SD: SPD \\<50% decreased from baseline, but \\<25% increased from nadir) and clinical performance status with steroid dose information. The DCR as assessed by BICR is presented.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG000","title":"Cohort C: Gastric Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG001","title":"Cohort D1: Colorectal Cancer (Lenva + Pembro)"},{"description":"Participants received Lenva 24 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG002","title":"Cohort D2: Colorectal Cancer (Lenva)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG003","title":"Cohort E: Glioblastoma Multiforma (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG004","title":"Cohort F: Biliary Tract Cancer (Lenva + Pembro)"},{"description":"Participants received Pembro 200 mg via IV infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (up to 2 years) PLUS Lenva 20 mg via oral capsule QD up to at least 2 years. Participants continued study intervention until progressive disease or unacceptable toxicity.","id":"OG005","title":"Cohort G: Pancreatic Cancer (Lenva + Pembro)"}],"paramType":"NUMBER","populationDescription":"All allocated participants who received at least 1 dose of study intervention. Per protocol, only data for Cohorts C, D1, D2, E, F, and G were presented for this endpoint.","reportingStatus":"POSTED","timeFrame":"Up to approximately 66 months","title":"Disease Control Rate (DCR) Per RECIST 1.1 or RANO Criteria (GBM Only) by BICR","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}